摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3-二氢-1H-喹啉-4-酮 | 4295-36-7

中文名称
2,3-二氢-1H-喹啉-4-酮
中文别名
1,2,3,4-四氢-4-喹啉酮盐酸盐;1,2,3,4-四氢喹啉-4-酮;2,3-二氢-1H-喹啉-4-酮盐酸盐;2,3-二氢-4-喹啉酮
英文名称
2,3-dihydroquinolin-4(1H)-one
英文别名
2,3-dihydro-1H-quinolin-4-one;2,3-dihydro-4(1H)-quinolone;1,2,3,4-tetrahydro-quinolin-4-one
2,3-二氢-1H-喹啉-4-酮化学式
CAS
4295-36-7
化学式
C9H9NO
mdl
——
分子量
147.177
InChiKey
BUWPZNOVIHAWHW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    44 °C
  • 沸点:
    195 °C(Press: 20 Torr)
  • 密度:
    1.142±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存储条件:0至10℃;应保存在惰性气体中,并避免与空气接触。

SDS

SDS:e8e9a74b0d8f5fd69dd8aad42bf49707
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2,3-Dihydro-1h-quinolin-4-one
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2,3-Dihydro-1h-quinolin-4-one
CAS number: 4295-36-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9NO
Molecular weight: 147.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2,3-二氢-1H-喹啉-4-酮可用作有机中间体,并且是一种肾上腺素能阻断剂。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    2,3-二氢-1H-喹啉-4-酮 在 sodium hydride 、 cesium fluoride 作用下, 以 N,N-二甲基甲酰胺乙腈 、 mineral oil 为溶剂, 反应 38.0h, 生成 甲基-蒽酮
    参考文献:
    名称:
    Formation of Acridones by Ethylene Extrusion in the Reaction of Arynes with β-Lactams and Dihydroquinolinones
    摘要:
    N-Unsubstituted beta-lactams react with a molecule of aryne by insertion into the amide bond to form a 2,3-dihydroquinolin-4-one, which subsequently reacts with another molecule of aryne to form an acridone by extrusion of a molecule of ethylene. 2,3-Dihydroquinolin-4-ones react under the same reaction conditions to afford identical results. This is the first example of ethylene extrusion in aryne chemistry.
    DOI:
    10.1021/jo3011073
  • 作为产物:
    描述:
    3-(2-aminophenyl)propyn-1-ol 在 tin(ll) chloride 作用下, 以 叔丁醇 为溶剂, 反应 1.0h, 以66%的产率得到2,3-二氢-1H-喹啉-4-酮
    参考文献:
    名称:
    Synthetic Studies on Plakinidines
    摘要:
    DOI:
    10.3987/com-18-s(f)26
点击查看最新优质反应信息

文献信息

  • ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF
    申请人:Bayburt Erol K.
    公开号:US20080153871A1
    公开(公告)日:2008-06-26
    The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar 1 , L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 , Y 2 , and Y 3 , are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
    本申请涉及的化合物是TRPV1拮抗剂,其化学式为(I),其中变量Ar1,L1,R1,R2,R3,R4,R5,Y1,Y2和Y3如描述中所定义,对于治疗由辣椒素受体活性引起或加剧的疾病是有用的。
  • Diamine derivatives
    申请人:Ohta Toshiharu
    公开号:US20050020645A1
    公开(公告)日:2005-01-27
    A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
    通用式(1)表示的化合物: Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4(1) 其中R1和R2是氢原子或类似物;Q1是饱和或不饱和的、5-或6-成员环烃基,可以被取代,或类似物;Q2是单键或类似物;Q3是一个基团,其中Q5是具有1至8个碳原子的烷基基团,或类似物;T0和T1是羰基团或类似物;其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征(SIRS)、多器官功能障碍综合征(MODS)、体外循环期间的血栓形成,或抽血时的血液凝结。
  • [EN] INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DE NOROVIRUS ET DE CORONAVIRUS
    申请人:COCRYSTAL PHARMA INC
    公开号:WO2021206876A1
    公开(公告)日:2021-10-14
    Compounds of Formula (I) and methods of inhibiting the replication of viruses in a biological sample or patient, of reducing the amount of viruses in a biological sample or patient, and of treating a virus infection in a patient, comprising administering to said biological sample or patient an effective amount of a compound represented by Formula (I), a compound of Table A or B or a pharmaceutically acceptable salt thereof.
    公式(I)化合物及抑制生物样本或患者中病毒复制、减少生物样本或患者中病毒数量、以及治疗患者病毒感染的方法,包括向所述生物样本或患者投与由公式(I)表示的化合物、表A或B中的化合物或其药用可接受盐的有效量。
  • Asymmetric Synthesis of Cyclopentene-Fused Tetrahydroquinolines via N-Heterocyclic Carbene Catalyzed Domino Reactions
    作者:Long Zhao、Sun Li、Lei Wang、Shun Yu、Gerhard Raabe、Dieter Enders
    DOI:10.1055/s-0036-1591995
    日期:2018.7
    domino yields and stereoselectivities. A new strategy for the N-heterocyclic carbene catalyzed asymmetric synthesis of cyclopentene-fused tetrahydroquinoline derivatives has been developed. The one-pot organocatalytic domino protocol allows a direct entry to the characteristic cyclopenta[c]tetrahydroquinoline core of many alkaloids and some potential drugs employing readily available quinolinone and enal
    摘要 已经开发出一种新的策略,用于N-杂环卡宾催化的不对称合成环戊烯稠合的四氢喹啉生物。一锅法有机催化多米诺协议允许直接进入许多生物碱和某些潜在药物的特征性环戊并[ c ]四氢喹啉核心,这些药物采用容易获得的喹啉酮和烯类底物,具有良好的多米诺产量和立体选择性。 已经开发出一种新的策略,用于N-杂环卡宾催化的不对称合成环戊烯稠合的四氢喹啉生物。一锅法有机催化多米诺协议允许直接进入许多生物碱和某些潜在药物的特征性环戊并[ c ]四氢喹啉核心,这些药物采用容易获得的喹啉酮和烯类底物,具有良好的多米诺产量和立体选择性。
  • PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT
    申请人:Ashikawa Masanori
    公开号:US20120004197A1
    公开(公告)日:2012-01-05
    Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R 1 , R 2 , R 2′ , R 3 and R 3′ independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, or the like; A represents N—R 11 , a sulfur atom, or an oxygen atom; R 11 represents a hydrogen atom, a C 1-6 alkyl group, or the like; B represents a C 6-14 aryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.
    揭示了一种具有低分子量的化合物,具有增强EPO产生和/或增强血红蛋白产生活性的化合物。具体揭示了一种EPO产生增强剂和/或血红蛋白产生增强剂,包括1-酰基-4-(取代氧基、取代基或取代基)-1,2,3,4-四氢喹啉生物,更具体地说是由通式(1)表示的四氢喹啉化合物【其中R1、R2、R2'、R3和R3'独立地表示氢原子、C1-6烷基或类似物;R4、R5、R6、R7、R8、R9和R10独立地表示氢原子、卤素原子、C1-6烷基或类似物;A表示N—R11、原子或氧原子;R11表示氢原子、C1-6烷基或类似物;B表示C6-14芳基或5-至10-成员杂环基;n表示0或1的整数】,四氢喹啉化合物的盐,或四氢喹啉化合物或其盐的溶剂化合物。
查看更多